Skip to content
Study details
Enrolling now

Study of SGR-1505 in Mature B-Cell Neoplasms

Schrödinger, Inc.
NCT IDNCT05544019ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

52

Study length

about 3 years

Ages

18+

Locations

16 sites in AZ, DE, FL +10

What this study is about

This trial is testing a treatment called SGR-1505 for people with certain types of mature B-cell cancers. The goal is to see if the treatment is safe and how well it works, as well as find the highest dose that can be given safely.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take SGR-1505

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Nature and number of incidences of dose limiting toxicity (DLT)., Nature, severity, and number of incidences of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation.

Secondary: Disease Control Rate, Duration of Response (DOR), Objective Response Rate (ORR), SGR-1505 Area Under the Concentration Versus Time Curve (AUC), SGR-1505 Maximal Plasma Concentration (Cmax), SGR-1505 Time to Maximal Plasma Concentration (tmax)

Body systems

Oncology